-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Roche announced an investment of $290 million to support the development of Freenome colorectal cancer detection technology
Freenome's test is being evaluated in the PREEMPTCRC trial, which is expected to enroll approximately 25,000 patients and is expected to be the largest registry of screening trials for CRC in asymptomatic, average-risk adults in the United States.
Freenome is an innovative CRC screening test that attempts to detect early-stage colorectal cancer using routine blood draws
Colorectal cancer is the third most common cancer in the world
For Roche, the big investment in Freenome will also strengthen the company's diagnostics capabilities
Freenome expects to initiate additional clinical studies in multiple cancer indications in February of this year
Freenome has raised more than $1.
Original English text: https:// href="https://" target="_blank" _href="https://" textvalue="https://">https://